Document is current
Any future updates will be listed below
-
Authors
Urciuolo, Anna https://orcid.org/0000-0001-7571-9747
Giobbe, Giovanni Giuseppe https://orcid.org/0000-0001-6958-7303
Dong, Yixiao
Michielin, Federica
Brandolino, Luca
Magnussen, Michael https://orcid.org/0000-0003-3054-9806
Gagliano, Onelia https://orcid.org/0000-0002-2571-3176
Selmin, Giulia
Scattolini, Valentina https://orcid.org/0000-0002-0855-9402
Raffa, Paolo
Caccin, Paola
Shibuya, Soichi https://orcid.org/0000-0002-4274-1312
Scaglioni, Dominic https://orcid.org/0000-0002-0441-2198
Wang, Xuechun
Qu, Ju
Nikolic, Marko https://orcid.org/0000-0001-6304-6848
Montagner, Marco https://orcid.org/0000-0003-3080-2138
Galea, Gabriel L. https://orcid.org/0000-0003-2515-1342
Clevers, Hans https://orcid.org/0000-0002-3077-5582
Giomo, Monica https://orcid.org/0000-0002-7690-1054
De Coppi, Paolo https://orcid.org/0000-0002-1659-0207
Elvassore, Nicola https://orcid.org/0000-0002-7029-6287
- License Information
-
More Information
Article History
Received: 26 October 2021
Accepted: 6 April 2023
First Online: 30 May 2023
Competing interests
: N.E. and O.G. have an equity stake in ONYEL Biotech s.r.l. A.U. and N.E. are inventors of a patent for the use of HCC- and CMM-hydrogels (patent applicant: ONYEL Biotech s.r.l.; patent number EP4138941). All other authors have no competing interests.
